Movatterモバイル変換


[0]ホーム

URL:


CN100443092C - Granulocyte raised drug comprising cepharanthine - Google Patents

Granulocyte raised drug comprising cepharanthine
Download PDF

Info

Publication number
CN100443092C
CN100443092CCNB2006101279065ACN200610127906ACN100443092CCN 100443092 CCN100443092 CCN 100443092CCN B2006101279065 ACNB2006101279065 ACN B2006101279065ACN 200610127906 ACN200610127906 ACN 200610127906ACN 100443092 CCN100443092 CCN 100443092C
Authority
CN
China
Prior art keywords
chinese medicine
cepharanthine
medicine extract
group
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2006101279065A
Other languages
Chinese (zh)
Other versions
CN1927266A (en
Inventor
高熠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IndividualfiledCriticalIndividual
Priority to CNB2006101279065ApriorityCriticalpatent/CN100443092C/en
Publication of CN1927266ApublicationCriticalpatent/CN1927266A/en
Application grantedgrantedCritical
Publication of CN100443092CpublicationCriticalpatent/CN100443092C/en
Expired - Fee Relatedlegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Landscapes

Abstract

The invention discloses a pharmaceutical composition containing cepharanthine and Chinese medicinal extracts, and the use of the pharmaceutical composition in preparing medicament for the promotion of leucocyte proliferation.

Description

The shengbai drug that contains cepharanthine
Invention field
This invention relates to the treatment disease in the blood system, the Integrative Chinese-Western medicine of leukopenia and agranulocytosis.
Background technology
Leukopenia and agranulocytosis are internal medicine blood system commonly encountered diseases, frequently-occurring disease, and its pathogenic factor can or infect and other disease causes because of chemical factors such as medicine (as benzolism), and partly cause is not clear.Particularly in the therapeutic process of many tumor diseases, need to use chemotherapy or actinotherapy treatment mostly, these two kinds of therapies all can be killed and wounded human leukocytes in a large number, it is the important pathogenesis of primary disease, many tumour patients often can not continue to accept chemotherapy or radiotherapy because of leukopenia causes, so that lose the therapy apparatus meeting, cause the development and the deterioration of tumor.Therefore, the treatment primary disease is particularly treated the leukopenia problem in tumour patient radiotherapy, the chemotherapy process, becomes the key subjects of domestic and international medical circle.
Though modern medicine has had deep understanding for the cause of disease, but in treatment, still lack new means, Therapeutic Method does not have major progress in recent years, generally adopts group vitamins leukocyte increasing (as adenine phosphate), colony stimulating factor and use adrenocortical hormone to reduce the leukocyte that causes because of immunity to destroy.These therapies, curative effect is unsatisfactory, and with some serious adverse comparatively, has limited the clinical scope of application.
The traditional Chinese medical herbal treatment primary disease, general employing determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, vigorate qi and replenish the blood, grow methods such as anti-tonifying YANG, though some patient is had curative effect preferably, but it is cumbersome with decocting for Chinese herbal medicine, dose is excessive and the time is long, how can influence disadvantages such as appetite, it is very few that the clinical application that has limited tumour patient serves as based on the leukocyte increasing of Chinese medicine to raise variety in the existing market of Chinese medicine preparation of main effect, and generally be compound preparation, and flavour of a drug are many, curative effect is extensively and not special, and especially the effect of leukocyte increasing is slowly and not remarkable.
The objective of the invention is to, the medicine that provides a kind of Chinese medicine and western medicine to unite use, Chinese medicine and Western medicine can be brought into play synergism, reduce the side effect of Western medicine on the one hand, onset rapidly on the other hand.This medicine can be used for various acute and chronic leukopenias or agranulocytosis, is particularly useful for because of the above-mentioned disease due to tumor disease radiotherapy or the chemotherapy.In leukocyte increasing, there is not the toxic and side effects of other similar Western medicine, it is also few that degradation reacts under the appetite due to other Chinese medicine because of taking.
Summary of the invention
This invention compositions realizes as follows: by weight
96 parts of 1 part of Chinese medicine extract of cepharanthine
Wherein Chinese medicine extract prepares according to the method for putting down in writing in the Chinese patent CN1058908A description: 0.15 part of 0.2 part of Radix Salviae Miltiorrhizae of 0.5 part of Fructus Ligustri Lucidi of 1 part of Radix Astragali of Caulis Spatholobi
Earlier Caulis Spatholobi is carried out coarse pulverization, preparing burden in proportion with other three flavors medicine in the back, puts and soaked in the molten device 7-10 hour.Decoct with water respectively then three times, time was respectively 1.5,1,0.5 hours, three fried liquid are merged, slow fire be concentrated into 1: 1 (g: ml) elimination insoluble matter, add 95% ethanol to pure content 80%, left standstill 12 hours, filter, the molten partially recycled ethanol of alcohol gets pure clear paste, is required Chinese medicine extract.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in the medicine of preparation promotion leucocyte hyperplasia.
This Chinese medical concrete is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has the effect that promotes leucocyte hyperplasia more by force, i.e. leukogenic effect.
Cyclophosphamide 120mg/kg/ day is injected in healthy Kunming mouse abdominal cavity continuously, continuous three days, treat that peripheral blood kind leukocyte reduces to 1000/mm3After, begin to take and respectively organize medicine, set up leukopenia model after the mice chemotherapy, carry out the pharmacodynamics test that Pharmaceutical composition of the present invention promotes leucocyte hyperplasia.Each is organized medicine and used 7 days continuously, irritates stomach every day 1 time, 10 of every group of mices.
The test grouping:
1 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: extractum 0.96g/kg body weight as indicated above
3 cepharanthine groups: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight cepharanthine+extractum 0.96g/kg body weight mentioned above is irritated stomach.
GroupThe leukocyte number
Group 1 1018±107.2/mm3
Group 2 1942±111.7/mm3
Group 3 2214±185.2/mm3
Group 4 3042±196.7/mm3
This table shows that all there is significant difference (P<0.05) in each group (pure Chinese drug-treated group, cepharanthine group, compositions group) of treatment with model control group, and all there are significant difference (P<0.05) in compositions group and pure Chinese drug-treated group, compositions group and cepharanthine group.Show that there are cooperative effect in cepharanthine and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
ComponentThe Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio cepharanthine and Chinese medicine extract mentioned above at 1: 96.
Can produce the capsule that contains following component in a conventional manner:
ComponentThe Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Talcum 5.0
Wherein compositions is made up of with weight ratio cepharanthine and Chinese medicine extract mentioned above at 1: 96.

Claims (1)

CNB2006101279065A2006-09-012006-09-01Granulocyte raised drug comprising cepharanthineExpired - Fee RelatedCN100443092C (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CNB2006101279065ACN100443092C (en)2006-09-012006-09-01Granulocyte raised drug comprising cepharanthine

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CNB2006101279065ACN100443092C (en)2006-09-012006-09-01Granulocyte raised drug comprising cepharanthine

Publications (2)

Publication NumberPublication Date
CN1927266A CN1927266A (en)2007-03-14
CN100443092Ctrue CN100443092C (en)2008-12-17

Family

ID=37857496

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CNB2006101279065AExpired - Fee RelatedCN100443092C (en)2006-09-012006-09-01Granulocyte raised drug comprising cepharanthine

Country Status (1)

CountryLink
CN (1)CN100443092C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN101780142B (en)*2010-03-172011-09-14宁波市鄞州昌达生物科技有限公司Leukogenic medicament containing lithium carbonate

Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN1058908A (en)*1990-08-151992-02-26于宗亮Prescription of oral liquor for increasing leucocyte and manufacturing process
CN1683973A (en)*2004-04-122005-10-19三星电子株式会社 Color filter substrate, display device and manufacturing method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN1058908A (en)*1990-08-151992-02-26于宗亮Prescription of oral liquor for increasing leucocyte and manufacturing process
CN1683973A (en)*2004-04-122005-10-19三星电子株式会社 Color filter substrate, display device and manufacturing method thereof

Also Published As

Publication numberPublication date
CN1927266A (en)2007-03-14

Similar Documents

PublicationPublication DateTitle
CN102258563A (en)Anti-cancer medicinal composition and Chinese medicinal composition
CN102210844B (en) A traditional Chinese medicine composition for treating chronic hepatitis and its preparation method
CN102225181B (en)Medicament for treating benign prostatic hyperplasia disease and preparation method thereof
CN101091769B (en)Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method
CN101062146A (en)Chinese traditional medicine for treating gastric cancer and bone cancer
CN100425252C (en)Medicine for treating leukopenia
US20050123636A1 (en)Use of the total coumarins jof cnidium monnieri in preparation of the medicament for treating psoriasis
CN101773545B (en)Leucocyte increasing medicament containing batyl alcohol
CN101439088B (en)Medicament for promoting leucocyte hyperplasia
CN103223149B (en)Chinese herb medicine composition for treating lung cancer
CN100443092C (en)Granulocyte raised drug comprising cepharanthine
CN100441205C (en)Medicine for treating blood system disease
CN101721471B (en)Leucocyte-raising medicine containing leucogen
CN114404490B (en)Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method
CN117323396A (en) A traditional Chinese medicine composition for treating hypertension in the elderly, stabilizing blood pressure fluctuations and reducing pulse pressure difference, and its preparation method and application
CN104435545B (en)A kind of Chinese medicine preparation for treating caused by benzene leukopenia
CN101439089B (en)Medicament containing oxymatrine
CN100381163C (en)Medicine comprising rilmenidine
CN101780142B (en)Leukogenic medicament containing lithium carbonate
CN101773660B (en)Medicament containing anubi-polypeotide
CN101559196B (en)Medicament for treating the hyperplasia of mammary glands and preparation method thereof
CN114191514B (en)Traditional Chinese medicine composition for preventing and treating phlegm-damp type obesity
CN100367956C (en)Medicine for treating hypertension
CN104940554A (en)Chinese herbal composition for treating heart diseases
CN100496543C (en)Injection for treating cardiac cerebrovascular disease and its preparation

Legal Events

DateCodeTitleDescription
C06Publication
PB01Publication
C57Notification of unclear or unknown address
DD01Delivery of document by public notice

Addressee:Ma Hongsen

Document name:Written notice of preliminary examination of application for patent for invention

C10Entry into substantive examination
SE01Entry into force of request for substantive examination
C14Grant of patent or utility model
GR01Patent grant
C17Cessation of patent right
CF01Termination of patent right due to non-payment of annual fee

Granted publication date:20081217

Termination date:20091009


[8]ページ先頭

©2009-2025 Movatter.jp